Arizona State Retirement System Sells 12,795 Shares of Medtronic PLC $MDT

Key Points

• Arizona State Retirement System trimmed its Medtronic stake by 3.4%, selling 12,795 shares and leaving it with 361,379 shares worth about $34.7 million.
• EVP Harry Skip Kiil sold 52,524 shares at an average $97.71 (≈$5.13M), reducing his holding by 61.6% to 32,768 shares.
• Medtronic is expanding its AI heart‑care footprint (CathWorks deal and related investments) and commercializing the Stealth AXiS surgical robot—moves drawing investor interest even as analysts remain mixed, with a consensus "Moderate Buy" and a $107.80 price target.

Arizona State Retirement System lessened its stake in Medtronic PLC (NYSE:MDT - Free Report) by 3.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 361,379 shares of the medical technology company's stock after selling 12,795 shares during the quarter. Arizona State Retirement System's holdings in Medtronic were worth $34,714,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of MDT. Curbstone Financial Management Corp lifted its position in shares of Medtronic by 1.8% during the 4th quarter. Curbstone Financial Management Corp now owns 5,594 shares of the medical technology company's stock worth $537,000 after buying an additional 100 shares in the last quarter. Baker Tilly Wealth Management LLC lifted its position in shares of Medtronic by 3.3% during the 4th quarter. Baker Tilly Wealth Management LLC now owns 3,221 shares of the medical technology company's stock worth $309,000 after buying an additional 102 shares in the last quarter. Riverbend Wealth Management LLC lifted its position in shares of Medtronic by 3.2% during the 3rd quarter. Riverbend Wealth Management LLC now owns 3,487 shares of the medical technology company's stock worth $332,000 after buying an additional 107 shares in the last quarter. Maseco LLP lifted its position in shares of Medtronic by 32.1% during the 4th quarter. Maseco LLP now owns 444 shares of the medical technology company's stock worth $43,000 after buying an additional 108 shares in the last quarter. Finally, Holistic Financial Partners lifted its position in shares of Medtronic by 3.0% during the 3rd quarter. Holistic Financial Partners now owns 3,697 shares of the medical technology company's stock worth $352,000 after buying an additional 109 shares in the last quarter. Institutional investors own 82.06% of the company's stock.

Insider Transactions at Medtronic

In related news, EVP Harry Skip Kiil sold 52,524 shares of the business's stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the sale, the executive vice president directly owned 32,768 shares in the company, valued at approximately $3,201,761.28. The trade was a 61.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.26% of the company's stock.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Completed CathWorks deal and new investment broaden Medtronic’s AI heart-care footprint (adds AI coronary diagnostics; also led a $100M investment in Pulnovo) — accelerates higher-margin, software-enabled offerings that can lift long-term growth. Read More.
• Positive Sentiment: Commercial progress: first surgeons have used the Stealth AXiS Autopilot surgical robotic platform — marks a tangible commercialization milestone for Medtronic’s robotics strategy and could support procedure volume and recurring revenue. Read More.
• Positive Sentiment: Investor interest in strategic moves — coverage noting a new GE HealthCare tie-up and Altaviva launch alongside M&A/launch activity has drawn attention to potential catalysts for re-rating if momentum continues. Read More.
• Neutral Sentiment: Analyst stance: Jefferies reiterated a Hold and says portfolio streamlining (including the diabetes spin-off) has benefits but is offset by a lower growth outlook and valuation compression — supports cautious investor positioning. Read More.
• Neutral Sentiment: UBS trimmed its price target to $90 from $104 and maintains a neutral rating — near-term analyst-driven cap on upside until execution or guidance surprises. Read More.
• Neutral Sentiment: Industry tailwinds: multiple market reports name Medtronic as a leading player in catheters, home/long-term care devices, and automated insulin-delivery systems — underscores TAM exposure but not immediate earnings impact. Read More.
• Neutral Sentiment: Corporate recognition: Medtronic’s CISO was honored at the HoustonCISO ORBIE Awards — positive PR but limited direct stock impact. Read More.
• Negative Sentiment: Share weakness and volatility: recent coverage highlights a notable YTD decline and short-term selloffs, which can pressure multiples and invite further analyst scrutiny if momentum doesn’t recover. Read More.
• Negative Sentiment: Recent daily dip: headlines note a larger-than-market intraday move downward in recent sessions — reinforcing near-term investor caution. Read More.

Analyst Ratings Changes

MDT has been the topic of several recent analyst reports. Wall Street Zen cut shares of Medtronic from a "buy" rating to a "hold" rating in a research report on Saturday, April 11th. Robert W. Baird lifted their target price on shares of Medtronic from $92.00 to $93.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 15th. Weiss Ratings cut shares of Medtronic from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Tuesday. Sanford C. Bernstein lifted their target price on shares of Medtronic from $111.00 to $112.00 and gave the stock an "outperform" rating in a research report on Friday, January 9th. Finally, Argus dropped their target price on shares of Medtronic from $125.00 to $115.00 and set a "buy" rating on the stock in a research report on Monday, April 6th. Fifteen investment analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $107.80.

Medtronic Stock Performance

Shares of MDT stock opened at $83.80 on Friday. The firm has a market cap of $107.59 billion, a price-to-earnings ratio of 23.34, a P/E/G ratio of 2.16 and a beta of 0.75. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. Medtronic PLC has a 52 week low of $79.93 and a 52 week high of $106.33. The firm's 50-day simple moving average is $90.10 and its two-hundred day simple moving average is $95.36.

Medtronic (NYSE:MDT - Get Free Report) last announced its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.34 by $0.02. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The business had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. During the same quarter in the previous year, the firm posted $1.38 earnings per share. The company's revenue for the quarter was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities analysts forecast that Medtronic PLC will post 5.57 earnings per share for the current year.

Medtronic Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, April 17th. Investors of record on Friday, March 27th were paid a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 3.4%. The ex-dividend date was Friday, March 27th. Medtronic's payout ratio is currently 79.11%.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.